RESUMO
Alzheimer's disease (AD) is a brain illness that causes cognitive impairment in the elderly, especially females, as a result of genetics, hormones, and life experiences. It becomes more severe with age and is associated with cardiovascular disease, hypertension, and diabetes. Beta-amyloid plaques and hyper phosphorylated Tau protein buildup are common clinical findings. Misfiling of amyloid precursor protein (APP) and Amyloid beta peptide (Aß) proteins contributes to Alzheimer's disease. Enzyme Acetylcholinesterase enzyme interacts with amyloid-beta, enhancing its accumulation in insoluble plaques, leading to successful treatment for Alzheimer's disease primarily based on lowering this enzyme. Treatments include using the Rivastigmine for mild, moderate, or severe Alzheimer's disease, which inhibits acetylcholinesterase, but may cause side effects; Solanine derivatives, nightshade toxin, it is cholinesterase inhibitory, may mitigate Alzheimer's illness is progressing. In this research utilized a molecular docking program, which is a computer's computational ability to determine the optimal position for a specific compound to bind to a protein or target, forming a target-ligand complex and displaying biological activity and aiding in the development of effective anti-AD treatments and understanding AD pathological mechanisms. The study examined complexes of 3LII (Acetylcholinesterase receptor) in the A and B chain with Solanine and Rivastigmine derivatives, using an in-silico approach. PyRx default sorter was used to improve docking accuracy. Four compounds were selected based on their higher binding affinities in chain A and B. The results showed that Solanine derivatives (alpha-Solanine, Beta1-Solanine and Beta2-Solanine) have higher binding strength (-9.0,-9.3 and -8.6) than Rivastigmine (-7.2) in chain A, and also the binding strength was high for the Solanine derivatives (alpha-Solanine, Beta1-Solanine, and Beta2-Solanine) (-9.0,-8.8 and -8.9) is higher than Rivastigmine (-6.0) in the chain B. Solanine derivatives showed higher binding strength with acetylcholinesterase, potentially for to reduce the progression of the disease.
RESUMO
A simple, rapid, accurate, and sensitive UV-Visible spectrophotometric method has been developed to estimate ephedrine hydrochloride (Eph) in pharmaceutical drugs. This method is based on preparing chelate complex through the reaction between Eph and cobalt ion (Co (II)). Ephedrine identification is done as an Eph - Co (II) complex after extraction by chloroform at λ max 389 nm. In this work, the optimum operation conditions such as pH, buffer volume, Co ion concentration, time of reaction and extraction, temperature, and water to organic volume ratio were determined. The linearity range of Eph has observed in the range between 1 and 80 ppm, at a wavelength of 387 nm with molar absorptivity range between 3.1867 × 103 to 1.6941 × 103(L·mol-1·cm-1) and metal to legend ratio of two. The results obtaind from this study are as follow: relative standard deviation (RSD) percentage is 0.303%, detection limit (D.L) = 0.94 ppm, Sandel's sensitivity (S) = 0.0135, relative error (Erel.) % = 0.039, recovery (Rec.) %=100.039. The results confirmed no interferences of excipients on the detection of Eph, and the proposed method has successfully applied for the determination of ephedrine-HCl in pure and pharmaceutical preparations. This method has several advantages, such as its low cost, high sensitivity, and ease of operation.
